Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
Investing20d
AstraZeneca reports positive results in nasal polyp trial
WILMINGTON, Del. - AstraZeneca (NASDAQ:AZN) and Amgen (NASDAQ:AMGN) have announced positive outcomes from the Phase III WAYPOINT trial of TEZSPIRE (tezepelumab) for patients with severe chronic ...
BioSpace23d
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
In Part A, children who received a higher dose of Dupixent (n=37) based on a weight-based dosing regimen experienced the following outcomes, compared to placebo (n=34) at 16 weeks: 68% achieved ...
Onlymyhealth24d
From Allergies to Asthma, These Conditions Can Trigger Nasal Polyps
Nasal polyps are soft, painless growths on the lining of your nasal passages or sinuses, often resulting from chronic inflammation. While these benign growths themselves are not harmful ...
IEEE2mon
Multi-View Network for Colorectal Polyps Detection in CT Colonography
Abstract: Early diagnosis of colorectal polyps, before they turn into cancer, is one of the main keys to treatment. In this work, we propose a framework to help radiologists in reading CT scans and ...
pharmaphorum3y
Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polyps
Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...